PLIANT THERAPEUTICS, INC.PLRXEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Pliant Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel targeted therapies for fibrotic diseases. Its pipeline includes candidate treatments for idiopathic pulmonary fibrosis, liver fibrosis and other chronic fibrotic conditions, with primary U.S. operations focused on addressing global unmet patient medical needs.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Deep Track Capital, LP | 9.60% | 5.8M | — | 2024-02-14 |
| T. ROWE PRICE ASSOCIATES, INC. | 8.00% | 4.8M | ▲ +1.70pp | 2024-11-14 |
| BlackRock, Inc. | 8.00% | 4.8M | — | 2024-01-25 |
| FMR LLC | 6.62% | 4.0M | — | 2024-02-09 |
| Redmile Group, LLC | 5.30% | 3.2M | ▲ +0.80pp | 2024-11-14 |
| The Vanguard Group | 5.12% | 3.1M | — | 2024-02-13 |
| Paradigm BioCapital Advisors LP | 5.03% | 3.1M | — | 2024-10-04 |
| Blue Owl Capital Holdings LP | 4.94% | 3.0M | ▼ -0.08pp | 2024-11-14 |
| First Light Asset Management, LLC | 3.08% | 1.9M | ▼ -2.99pp | 2024-11-14 |
| Third Rock Ventures III, L.P. | 0.60% | 339.2K | — | 2024-02-14 |
| Laurion Capital Management LP | 0.00% | 729.1M | ▼ -5.98pp | 2024-11-12 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
No transactions match these filters.